The predictive factors of α1-D/A adrenoceptor antagonist, naftopidil, dose increase therapy for male lower urinary tract symptoms caused by benign prostatic hyperplasia: INFORM study

INTRODUCTION: We evaluated the predictive factors which affect the efficacy of naftopidil 50 mg/day therapy and dose increase therapy to administration of 75 mg/day after an initial dose of 50 mg/day. MATERIALS AND METHODS: A total of 92 patients with male lower urinary tract symptoms/benign prostat...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanuma, Yasushi, Tanaka, Yoshinori, Takeyama, Ko, Okamoto, Tomoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532895/
https://www.ncbi.nlm.nih.gov/pubmed/28794594
http://dx.doi.org/10.4103/UA.UA_23_17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532895/
https://www.ncbi.nlm.nih.gov/pubmed/28794594
http://dx.doi.org/10.4103/UA.UA_23_17

Ejemplares similares